On January 17, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
For more information, read the FDA announcement and the AstraZeneca press release.
Posted 1/28/2025
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
